Catalog No.: PC-20589Not For Human Use, Lab Use Only.
Abemaciclib (LY2835219) is a potent, selective and ATP-competitive CDK4/6 inhibitor with Ki values of 0.6 and 2.4 nM for CDK4/cyclin D1 and CDK6/cyclin D1, respectively.
Abemaciclib (LY2835219) is a potent, selective and ATP-competitive CDK4/6 inhibitor with Ki values of 0.6 and 2.4 nM for CDK4/cyclin D1 and CDK6/cyclin D1, respectively.
Abemaciclib (LY2835219) inhibits CDK4/cyclin D1 and CDK6/cyclin D1 with IC50 of 2 and 10 nM, respectively, with high selectivity against CDK1/cyclin B1, CDK2/cyclin E, and CDK7/Mat1/cyclin H.
Abemaciclib (LY2835219) is a potent inhibitor of Rb phosphorylation (IC50=120 nM) in colo-205 cells, induces a complete cell cycle arrest and suppresses expression of several Rb-E2F-regulated proteins.
Abemaciclib (LY2835219) inhibits tumor growth in human tumor xenografts representing different histologies in tumor-bearing mice.
Abemaciclib (LY2835219) in combination with gemcitabine enhanced in vivo antitumor activity without a G1 cell cycle arrest in calu-6 xenografts.
